NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation. NGs are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intracellular barriers, and fast clearance from normal tissues. NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of cancer and inflammatory diseases.
NanoGhost is a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site. The technology has already proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice.
The website also provides information about their technology and its characteristics such as being targeted & selective, versatile and having a wide payload size range.
Location: Israel, Tel Aviv District, Tel Aviv
Employees: 11-50
Total raised: $5M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.12.2019 | - | $5M | - |